Egle Therapeutics Appoints Christophe Quéva as CEO to Lead Clinical Advancement

Egle Therapeutics has announced the appointment of Dr. Christophe Quéva as its new Chief Executive Officer. Dr. Quéva, who brings over 20 years of experience in immuno-oncology and has held senior roles at leading biopharmaceutical companies such as Gilead Sciences and Amgen, will lead Egle as it transitions its preclinical assets into clinical-stage development. Egle Therapeutics, backed by Bioqube Ventures, is focused on developing therapies targeting regulatory T cells for oncology and autoimmune diseases. The company is preparing to advance its leading drug candidates, EGL-001 for oncology and EGL-003 for autoimmune diseases, into clinical trials. Dr. Quéva's appointment is seen as a strategic move to leverage his deep expertise in drug development and regulatory processes to drive the company's clinical and technological advancements.